SMi Group's 3rd annual Cancer Vaccines 2014 conference returns to London this September

1. CHAIR FOR 2014:
Dr Joseph Melenhorst, Director of the Product
Development & Correlative Sciences
Laboratory, University of Pennsylvania
KEY SPEAKERS INCLUDE:
• Tom Lillie, Oncology International Therapeutic Head, Amgen
• Harpreet Singh, Managing Director, Chief Scientific Officer,
Co-Founder, Immatics GmbH
• Eric Leire, Chief Executive Officer, DanDrit Biotech
• Professor Alex Karlsson-Parra, Chief Scientific Officer, Immunicum
• Christian Ottensmeier, Professor in Experimental Cancer
Medicine and Honorary Consultant in Medical Oncology,
University of Southampton
• Dr Birgit Scheel, Director Program Management Oncology,
CureVac GmbH
WHY ATTEND IN 2014:
• Insight into a Perfect Partnership – A University of Pennsylvania
and Novartis Collaboration! Hear it here first: Assessing
techniques involved in removing a patient's T cells and
inserting new genetic material to enable the T cells to attack
and kill cancer cells
• Assessing Oncolytic Vaccines: Reviewing developments from
Amgen and Psioxus Therapeutics
• What are the key questions in Cancer Immunotherapy?
Professor Christian Ottensmeier attacks this question head on!
• Evaluating analytical advances for Cancer Vaccines with an
insight from Key Opinion Leaders at Immatics GmbH,
Vaccinogen and the University of Southampton
SMi Presents the 3rd Annual Conference on…
15 - 16
SEPT
2014Holiday Inn Regents Park, London, UK
Cancer Vaccines
@SMIpharm
PLUS AN INTERACTIVE POST-CONFERENCE WORKSHOP
Wednesday 17th September 2014, Holiday Inn Regents Park, London, UK
Tumour Genomic Heterogeneity in Immunotherapy
Workshop Leader: Michael Hanna, Chairman and Chief Executive Officer, Vaccinogen
8.30am – 12.30pm
www.cancer-vaccinesevent.com
BOOK BY MAY 30TH AND SAVE £300 AND BY JUNE 30TH FOR £100
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
Quantify Strategies to Enhance Cancer
Vaccine Research and Development
Sponsored by

2. Register online at: www.cancer-vaccinesevent.com • Alternatively f
Cancer Vaccines
Day One | Monday 15th September 2014
8.30 Registration & Coffee
9.00 Chairman's Opening Remarks
Dr Joseph Melenhorst, Director of the Product Development
& Correlative Sciences laboratory, University of Pennsylvania
CANCER VACCINE DEVELOPMENT
OPENING ADDRESS
9.10 Therapeutic Vaccines for the treatment of Cancer
– Where are we now?
•Potential of protein based vaccines
•A new vector promoting an integrated immune
response
•Multi-epitopic immune response monitored
in the periphery and at the tumor site
•Persistent effector T cells
Madiha Derouazi, CEO, Amal Therapeutics
9.50 T-VEC – Oncolytic immunotherapy in metastatic melanoma
•Reviewing the developments of Oncolytic vaccines for the
treatment of cancer
•Assessing vaccine delivery – oncolytic virus
phase III
•Evaluating data from a trial of oncolytic
immunotherapy to demonstrate activity in
melanoma
Tom Lillie, Oncology International Therapeutic
Head, Amgen
10.30 Morning Coffee
11.00 Case Study: Oncolytic vaccines – A step into cancer
immunotherapy!
•Reviewing the developments of Oncolytic
vaccines for the treatment of cancer
•Assessing vaccine delivery – clinical trial
developments
John Beadle, CEO, Psioxus Therapeutics
11.40 T cell immune monitoring: reliability, standardisation and use
in clinical trials
•Validity of assays for use in clinical trials
•Data from proficiency panels
•Advantages in cancer vaccines and cellular
immunotherapies
Lisolette Brix, Chief Operational Officer, Immudex
12.20 Networking Lunch
1.30 Cancer vaccination in the era of immunomodulatory
immunotherapy
•Recent successes with immunomodulatory antibodies raise
the question of the necessity for pursuing cancer vaccine
development
•Immunomodulatory antibodies can only “take the brakes
off” immune responses
•Cancer vaccines and adoptive immunotherapies will be
part of the combination treatments required to cure
cancer
Graham Pawelec, Professor of Experimental Immunology,
University of Tuebingen
2.10 Activated allogeneic DCs as an off-the-shelf vaccine
adjuvat in cancer immunotherapy
•Immunicum has developed a cellular adjuvant consisting
of pre-activated DCs producing high levels of DC-
recruiting and DC-activating factors in a sustained fashion
•This concept doesn´t require MHC-compatibility between
injected cells and the patient and therefore introduces the
possibility of using pre-produced and freeze-stored DCs
from healthy blood donors as an ”off-the-shelf” vaccine
adjuvant
•Data from an ongoing phase I/II clinical trial indicate that
intratumoral injection (thus using the patient´s own tumor
as antigen source) of pre-activated allogeneic
DCs is safe and induce a systemic CTL-mediate
d anti-tumor response that may prolong survival
in patients with metastatic renal cancer
Professor Alex Karlsson-Parra, Chief Scientific
Officer, Immunicum
2.50 Afternoon Tea
3.20 Phase I/II trial of a novel antibody DNA immunotherapy,
SCIB1 ImmunoBody which targets CD64, in the treatment of
Melanoma
•We demonstrate that SCIB1 is safe
•Of 25 evaluable patients, 23 have shown
immune responses following repeat dosing
with SCIB1
•Detection of objective clinical responses
and overall survival times are encouraging
Lindy Durrant, Joint CEO, Scancell plc.
4.00 Developments in the Field of Cancer Vaccines - Moving Forward
Reserved Speaking Slot
Dr. Eric Leire, CEO, DanDrit Biotech
4.40 Chairman's Closing Remarks and Close of Day One
Official Media Partner

3. Want to know how you
can get involved?
Interested in promoting
your services to this
market?
Contact Teri Arri,
SMi Marketing
on +44 (0) 207 827 6162,
or email:
tarri@smi-online.co.uk
Supported by
ax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
Day Two | Tuesday 16th September 2014
8.30 Registration & Coffee
9.00 Chairman's Opening Remarks
Dr Joseph Melenhorst, Director of the Product Development
& Correlative Sciences laboratory, University of Pennsylvania
IMPROVING SUCCESS IN VACCINE RESEARCH & DEVELOPMENT
OPENING ADDRESS
9.10 A Perfect Partnership – A University of Pennsylvania and
Novartis Collaboration!
•Assessing techniques involved in removing a patient's
T cells and inserting new genetic material to enable the
T cells to attack and kill cancer cells
•Is a combination therapy key?
•Assessing the modification of cells to infuse back
into the patient's body following chemotherapy
to fight the remaining tumors
Dr Jos Melenhorst, Director of the Product
Development & Correlative Sciences laboratory,
University of Pennsylvania
9.50 RNActive® for cancer immunotherapy
•Targeting immunotherapy candidates for the treatment of
cancer by harnessing the natural power of the immune
system to fight disease
•Current pivotal trials- updates and reviews
of the current developments
Dr Birgit Scheel, Director Program
Management Oncology, CureVac GmbH
10.30 Morning Coffee
11.00 High expectations and harnessing the body’s immune system
•Basis for and practical limits of immunotherapies
•Pre-clinical models
•Clinical progress in cell-based vaccines
John Maudsley, CEO, Cancer Vaccines Ltd
11.40 What are the key questions in Cancer Immunotherapy?
•Using head and neck cancer squamous cell carcinoma we
assess:
•Understanding immune event: the importance of where to
look
•How can we assess the tumour and how can we measure
success?
•What can we learn from failure?
Christian Ottensmeier, Professor in Experimental
Cancer Medicine and Honorary Consultant in
Medical Oncology, University of Southampton
12.20 Networking Lunch
ANALYTICAL ADVANCES FOR CANCER VACCINES
1.30 Head and neck cancer immunotherapy: translating
laboratory science into a clinical program
•Which HNSCC cancers are immunogenic?
•What are the attractive targets for (HNSCC)
immunotherapy how do we set up the most informative
trials how can we optimize the information we gain
Dr Emma King, CRUK Senior Lecturer in Head and Neck
Surgery, Southampton University
2.10 Biomarker-guided development of novel cancer vaccines -
from off-the-shelf to actively personalized
•Discovery of novel antigens for cancer immunotherapy
using high-throughput mass spectrometry
•Biomarker-guided clinical development of such novel
antigens in renal, colorectal and brain cancer
•Moving beyond current concepts of personalized
medicine: actively personalized vaccines in
glioma
Harpreet Singh, Managing Director, Chief Scientific
Officer, Co-Founder, Immatics GmbH
2.50 Afternoon Tea
3.20 The Provacative issue of tumor Genomic Heterogeneity in
immunotherapy
•The impact in Antigen discovery for Cancer Vaccines
•Patient population selection for treatment
•In vivo and in vitro monitoring of the treatment and clinical
endpoints
•Potential for development of epitope based vaccines for
treatment and prevention
Michael Hanna, Chairman and Chief Executive Officer,
Vaccinogen
4.00 DISCUSSION PANEL:
Assessing regulatory approval and clinical trial design
•What are the implications of manufacturing?
•What are the regulatory requirements from phase IIb to III?
Panelists:
Christian Ottensmeier, Professor in Experimental Cancer
Medicine and Honorary Consultant in Medical Oncology,
University of Southampton
John Maudsley, CEO, Cancer Vaccines Ltd
Michael Hanna, Chairman and Chief Executive Officer,
Vaccinogen
4.40 Chairman’s Closing Remarks and Close of Day Two

4. Overview of workshop:
Science recently highlighted cancer immunotherapy as the “2013 Breakthrough of the
Year”. More to the point, they stated "this year marks a turning point in cancer, as long-
sought efforts to unleash the immune system against tumors are paying off - even if the
future remains a question mark." Most of the celebration involves the compelling results
of targeted agents designed to reactivate the immune system by manipulating the
PD-1/PD-L1 and CTLA-4 pathways. By blocking these recently identified suppressor
molecules, these targeted therapies are designed to unleash the immune system either
as monotherapies or in combination with traditional cytotoxic chemotherapy. While
these investigations have provided a novel direction for enhancing cancer treatment,
additional technologies still need to be developed to specifically identify tumor-
associated antigens (TAAs) to harness the full power of the immune system. Active
specific immunotherapy (ASI) with cancer vaccines has the potential to be that
transformative technology by embracing the recently demonstrated genomic
heterogeneity of tumor cells which represent the entire antigenic diversity of each
patient’s primary tumor.
Why should you attend this workshop:
The Provacative Issue of tumor Genomic Heterogeneity in Immunotherapy.
• The impact in Antigen discovery for Cancer Vaccines.
• Patient population selection for treatment.
• In vivo and in vitro monitoring of the treatment and clinical endpoints.
• Potential for development of epitope based vaccines for treatment and
prevention.
HALF-DAY POST-CONFERENCE WORKSHOP
Wednesday 17th Septemeber 2014 | 8.30am – 12.30pm | Holiday Inn Regents Park, London, UK
Tumour Genomic Heterogeneity in Immunotherapy
Workshop Leader: Michael Hanna, Chairman and Chief Executive Officer, Vaccinogen
About the workshop host:
Michael G. Hanna, Jr., Ph.D. Chairman and Chief Executive Officer, Vaccinogen
Dr. Hanna is the founder of Vaccinogen and the discoverer and developer of OncoVAX® an autologous vaccine designed to provoke a specific
immune response against colon cancer cells. His previous accomplishments include Chairman (Emeritus) and Chief Scientific Officer of Intracel
Resources, Chief Operating Officer of Organon Teknika/Biotechnology Research Institute and Sr. Vice President of Organon Teknika Corporation. Prior
to that (1975-1982) Dr. Hanna was Director of the National Cancer Institute, Frederick Cancer Research Center.
Dr. Hanna received a doctoral degree in experimental pathology and immunology from the University of Tennessee. He has over 225 publications
to his credit, has 11 patents in immunotherapy and has been the recipient of numerous honors, and served on many editorial boards.
About the Organisation:
Vaccinogen, Inc. is a cancer vaccine company that is clinically testing its OncoVAX® treatment which is designed to prevent the
recurrence of colon cancer and potentially other solid tumors. It is a patented process that circumvents the extreme diversity of tumor
cells by leveraging a patient’s own live tumor cells to launch a broad immune response against colon cancer. The Company believes
that OncoVAX, at an optimum dose and regimen, is the first colon cancer vaccine to demonstrate effectiveness in both preventing
cancer recurrence after surgical resection of the primary tumor and addressing the diversity of cancer cells. OncoVAX has completed
five clinical studies, including a Phase III trial with the optimum dose and regimen. The Company expects to begin a pivotal Phase IIIb
trial under an FDA Special Protocol Assessment (SPA) classification in the fourth quarter of 2013. The SEC completed its review of
Vaccinogen’s Form 10 registration statement on October 16, 2013. The Company’s shares trade on the OTC.QB under the symbol
“VGEN”. More information is available at www.vaccinogeninc.com
Sponsored by Immudex provides MHC Dextramer reagents for quantification of antigen-specific T cells, and also
provides MHC Multimer and Elispot immune monitoring proficiency panel services. The overall goal is to
enable simple, accurate and reliable monitoring of antigen-specific cellular immunity, and to promote the
routine use of these technologies in vaccine development. www.immudex.com
Scancell is an AIM listed company developing novel treatments for cancer based on its proprietary
ImmunoBody® and Moditope® technology platforms which stimulate target specific high avidity T cells.
Scancell’s first ImmunoBody®, SCIB1, which is being developed for melanoma, has produced a potent
immune response and tumour destruction in late stage patients. www.scancell.co.uk
AGENDA:
8.30 Registration and Coffee
9.00 Assessing the impact in Antigen
discovery for Cancer Vaccines
10.00 Coffee Break
10.30 Reviewing the patient population
selection for treatment
11.30 Evaluating the in vivo/in vitro
monitoring of the treatment
and clinical endpoints
12.30 Closing of workshop

5. SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your
company’s marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your
client base within the context of an independent discussion specific to your industry.
Should you wish to join the increasing number of companies benefiting from sponsoring our conferences
please call: Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk
JUNE
Biobanking
23 - 24 June 2014, London
ADMET
30 June - 1 July 2014, London
Peptides
30 June - 1 July 2014, London
JULY
Lyophilisation
7 - 8 July 2014, London
BioNetworks
7 - 8 July 2014, London
Allergies
9 - 10 July 2014, London
Immunogenicity
14 - 15 July 2014, London
SEPTEMBER
Cancer Vaccines
15 - 16 September 2014, London
Biosimilars and Biobetters
29 - 30 September 2014, London
OCTOBER
European Pharmaceutical Pricing
and Reimbursement
13 - 14 October 2014, London
Orphan Drugs
20 - 21 October 2014, London
COPD: Novel Therapeutics and
Management Strategies
20 - 21 October 2014, London
Point of Care Diagnostics
- Market Opportunities and
Technology Trends
27 - 28 October 2014, London
NOVEMBER
Cell Based Assays
19 - 20 November 2014, London
Clinical Trials in CNS
19 - 20 November 2014, London
DECEMBER
Cold Chain Distribution
2 - 3 December 2014, London
SMi'S PHARMACEUTICAL PORTFOLIO 2014
Cancer Vaccines
15th & 16th September 2014A little more about the Chairman
Dr Joseph Melenhorst
Dr. Melenhorst built his career in human T cell immunology, leukemia biology, immunity and correlative sciences
starting with his Ph.D. studies at the Leiden University Medical Center, Leiden, Netherlands, followed by a post-
doctoral position and staff scientist position at the National Institutes of Health in Bethesda, Maryland. He studied the
immune pathogenesis of the bone marrow failure syndromes aplastic anemia, large granular lymphocyte leukemia
and myelodysplastic syndromes, acquiring expertise in advanced techniques such as high-resolution functional
flow cytometry and the cellular and molecular dissection of the human T cell repertoire. By combining these skills
with the manufacture of polyclonal and clonal T cell lines and exploiting the use of gene-modified activated T cells
as antigen presenting cells he prepared himself for a leadership role in the field of cellular therapies and correlative
sciences.
His expertise is in the in vitro generation and analysis of T cell reactivity with leukemic, viral, and allo-antigens; immune pathogenesis of
graft-versus-host disease and immune reconstitution post-transplant and immunotherapy, and his expert opinion is often consulted for
the review of manuscripts submitted to high-impact scientific journals such as Blood and the Journal of Immunology. In addition, Dr.
Melenhorst has contributed reviews to journals such as Blood, Cytometry, and Cytotherapy. In total Dr. Melenhorst’s publication record
consists of over 60 publications, including 10 invited reviews and commentaries in high-impact scientific journals, and six additional
research papers from his contributions at the NIH that have been submitted or are in preparation.
In August 2012, Dr. Melenhorst was recruited and appointed as Deputy Director of Clinical Cell and Vaccine Production Facility within
the Translational Research Program (TRP), Department of Pathology and Laboratory Medicine and the Abramson Cancer Center, and
in October of 2013 he assumed the role of Director of a new unit within TRP: the Product Development & Correlative Sciences (PDCS)
laboratory. Dr. Melenhorst’s interest in translational research is continued at the PDCS lab on the improvement of the potency of
chimeric antigen receptor-expressing T (CART) cells in certain leukemias and solid tumors, the understanding of the in vivo potency of
CART cells, and biomarkers of immunotherapy. Dr. Melenhorst is a highly original scientist who has originated and contributed to
innovations at the National Institutes of Health and the University of Pennsylvania.

6. FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor
South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK
CANCER VACCINES
Conference: Monday 15th & 16th September 2014, Holiday Inn Regents Park Hotel, London, UK Workshop: Wednesday 17th September 2014, London
4 WAYS TO REGISTER
www.cancer-vaccinesevent.com
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk
Payment: If payment is not made at the time of booking, then an invoice will be issued and must be
paid immediately and prior to the start of the event. If payment has not been received then credit
card details will be requested and payment taken before entry to the event. Bookings within 7 days
ofeventrequirepaymentonbooking.AccesstotheDocumentPortalwillnotbegivenuntilpayment
has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send a
substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing
that cancellation is made in writing and received at least 28 days prior to the start of the event.
Regretfully cancellation after this time cannot be accepted. We will however provide the
conferences documentation via the Document Portal to any delegate who has paid but is unable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to
provide documentation in these circumstances. We cannot accept cancellations of orders placed
for Documentation or the Document Portal as these are reproduced specifically to order. If we have
to cancel the event for any reason, then we will make a full refund immediately, but disclaim any
further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other
products and services. Unless you tick here □ we may also share your data with third parties offering
complementary products or services. If you have any queries or want to update any of the data that
we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit
our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the
attached letter.
Unique Reference Number
Our Reference LVP-116
Terms and Conditions of Booking
DELEGATE DETAILS
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
VENUE Holiday Inn, Regents Park, Carburton Street, London, W1W 5EE
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712
□ Book by 30th May to receive £300 off the conference price
□ Book by 30th June to receive £100 off the conference price
EARLY BIRD
DISCOUNT
Payment must be made to SMi Group Ltd, and received before the event, by one of
the following methods quoting reference P-116 and the delegate’s name. Bookings
made within 7 days of the event require payment on booking, methods of payment
are below. Please indicate method of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
Card Billing Address (If different from above):
LIVE STREAMING/ON DEMAND/ DOCUMENTATION
Unable to travel, but would like to watch the conference live, ask questions,
participate as if you were in the room. Price Total
□ Live Streaming £999.00 + VAT (UK) £1198.80
□ On demand £599.00 + VAT (UK) £718.80
(available 24 hours after the event)
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations - paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
PAYMENT
VAT
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on live
Streaming, on Demand, Document portal and literature distribution for all UK customers and
for those EU Customers not supplying a registration number for their own country here.
______________________________________________________________________________________________
CONFERENCE PRICES
I would like to attend: (Please tick as appropriate) Fee Total
□ Conference only £1499.00 +VAT £1798.80
□ Conference and Workshop £2098.00 +VAT £2517.60
□ Workshop only £599.00 +VAT £718.80
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers, and access to the
Document Portal. Presentations that are available for download will be subject to
distribution rights by speakers. Please note that some presentations may not be available
for download. Access information for the document portal will be sent to the e-mail
address provided during registration. Details are sent within 24 hours post conference.